{"id":28289,"date":"2015-06-01T09:11:01","date_gmt":"2015-06-01T09:11:01","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=28289"},"modified":"2015-06-11T12:05:29","modified_gmt":"2015-06-11T12:05:29","slug":"dual-ftaf-formulation-under-evaluation-by-ema","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/28289","title":{"rendered":"Dual F\/TAF formulation under evaluation by EMA"},"content":{"rendered":"<p><strong>Gilead press release<\/strong><\/p>\n<p><strong>On 28 May 2015, Gilead issues a press statement noting that regulatory submission for the dual formulation of FTC (emtricitabine) plus tenofovir alafenamide (TAF) has been accepted by the European Medicines Agency (EMA).<\/strong><\/p>\n<p>This includes two different doses for F\/TAF: 200\/10 mg and 200\/25 mg.<\/p>\n<p>Source:<\/p>\n<p>Gilead press statement. European Medicines Agency Validates Gilead&#8217;s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment. (28 May 2015).<br \/>\n<a href=\"http:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&amp;p=irol-newsArticle&amp;ID=2054021#sthash.qmj4GCeW.dpuf\">http:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&amp;p=irol-newsArticle&amp;ID=2054021#sthash.qmj4GCeW.dpuf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead press release On 28 May 2015, Gilead issues a press statement noting that regulatory submission for the dual formulation of FTC (emtricitabine) plus tenofovir alafenamide (TAF) has been accepted by the European Medicines Agency (EMA). This includes two different &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-28289","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/28289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=28289"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/28289\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=28289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=28289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=28289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}